When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.

Following risk management measures, ponatinib-associated adverse events in CML and ALL were shown to have decreased significantly since the drug’s approval.

Treatment with pirtobrutinib induced superior progression-free survival among heavily pretreated patients with relapsed or refractory CLL/SS previously treated with a covalent BTK inhibitor.

Secondary end points of the ASC4FIRST trial continue to show superior results with the use of asciminib, over standard-of-care TKIs in CML.

Treatment with acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over standard-of-care chemoimmunotherapy in patients with treatment-naive CLL.

Treatment with epcoritamab alone demonstrated deep responses in heavily pretreated patients with CLL, according to the expansion and optimization cohorts in the EPCORE CLL-1 trial.